National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov
In English | En español
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

Z-360
A selective, orally available, 1,5-benzodiazepine-derivative gastrin/cholecystokinin 2 (CCK-2) receptor antagonist with potential antineoplastic activity. Z-360 binds to the gastrin/CCK-2 receptor, thereby preventing receptor activation by gastrin, a peptide hormone frequently associated with the proliferation of gastrointestinal and pancreatic tumor cells. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)




Previous:yttrium Y 90 monoclonal antibody Hu3S193, yttrium Y 90 monoclonal antibody MN-14, yttrium Y 90 resin microspheres, yttrium Y 90-DOTA-chimeric monoclonal antibody cG250, yttrium Y 90-edotreotide
Next:Zactima, zalcitabine, Zanosar, Zarnestra, ZD6126

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov